Clinical trials: Recurrent Major Depression
Major Depressive Disorder
Combining Medications to Enhance Depression Outcomes
This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.
- Trial name
- CO-MED (NCT00590863)
- Testing
- Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
- Where
- 15 sites in United States
- Volunteers
- 665 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar Disorder
Prevention of Relapse & Recurrence of Bipolar Depression
The purpose of this study is to determine whether the long-term use of combined antidepressant plus mood stabilizer therapy is superior to mood stabilizer therapy alone in preventing the relapse and recurrence of bipolar…
- Trial name
- NCT00961961
- Testing
- Lithium / Fluoxetine
- Where
- 2 sites in United States
- Volunteers
- 177 people
- Sponsor
- University of Pennsylvania
Depressive Disorder, Major
Mindfulness Based Cognitive Therapy for Recurrent Depression
The purpose of this study is to investigate the effectiveness and possible mediating factors of Mindfulness Based Cognitive Therapy (MBCT) for recurrent depression.
- Trial name
- NCT01038765
- Testing
- Mindfulness Based Cognitive Therapy
- Where
- Netherlands
- Volunteers
- 220 people
- Sponsor
- Radboud University Medical Center
Major Depressive Disorder, Recurrent
Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)
The purpose of this study is to evaluate the safety and efficacy of filorexant (MK-6096) versus placebo as adjunctive treatment for major depressive disorder (MDD), in participants who are partial responders to antidepressant…
- Trial name
- NCT01554176
- Testing
- Filorexant
- Volunteers
- 129 people
- Sponsor
- Merck Sharp & Dohme LLC
Major Depressive Disorder
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder…
- Trial name
- NCT00985725
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 33 sites in United States
- Volunteers
- 143 people
- Sponsor
- Shire
Recurrent Major Depressive Disorder With Atypical Features
Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression.
- Trial name
- NCT00585585
- Testing
- betahistine dihydrochloride
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Cincinnati
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Depressive Disorder, Major, Unipolar Depression
Deep Brain Stimulation for Major Depressive Disorder
This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major…
- Trial name
- NCT00617162
- Testing
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 125 people
- Sponsor
- Abbott Medical Devices
Depressive Disorder, Major
European Deep Brain Stimulation (DBS) Depression Study
To evaluate the effects of two different programming settings of deep brain stimulation (DBS) in the subgenual white matter (Brodmann Area 25 WM) as an adjunctive treatment for treatment resistant Major Depressive Disorder…
- Trial name
- NCT01331330
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in France, Israel and 1 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
Depression
Adding an Insulin-Sensitizing Medication to Depression Treatment for People Who Are Depressed and Overweight
This study will determine whether the drug metformin improves the effects of traditional antidepressant medications in people who are overweight.
- Trial name
- NCT00834652
- Testing
- Sertraline, Metformin
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Washington University School of Medicine
Depressive Disorder, Major
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
- Trial name
- NCT00105989
- Testing
- Duloxetine
- Where
- 34 sites in United States, France and 4 more
- Volunteers
- 514 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Depression, Unipolar
Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
The purpose of this pilot study is to determine if taking a low dose of naltrexone in addition to an antidepressant medication can help treat relapse or recurrence in people with Major Depressive Disorder (MDD). The U.S.
- Conditions
- Major Depressive Disorder, Depression, Unipolar, Recurrence, Relapse
- Trial name
- NCT01874951
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Study of Aripiprazole in Patients With Major Depressive Disorder
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy…
- Trial name
- NCT00105196
- Testing
- Aripiprazole+ ADT
- Where
- 34 sites in United States
- Volunteers
- 349 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Relapse
Ketamine for Relapse Prevention in Recurrent Depressive Disorder
Randomised, controlled, parallel-group, pilot clinical trial of ketamine vs. midazolam for depression relapse prevention in persons at high risk.
- Conditions
- Depression, Relapse, Recurrent Depressive Disorder, Major Depressive Disorder
- Trial name
- KINDRED (NCT02661061)
- Testing
- Ketamine, Midazolam
- Where
- Ireland
- Volunteers
- 9 people
- Sponsor
- St Patrick's Hospital, Ireland
Major Depressive Disorder, Recurrent
Investigation of Brain Network Dynamics in Depression
This research study is being done to gain a better understanding about brain networks that may be involved in depression. The investigators plan to examine how these networks change after the brain is stimulated with…
- Trial name
- NCT01931995
- Testing
- TMS positively correlated DLPFC, TMS to negatively correlated DLPFC
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital